The changing landscape of second primary malignancies in multiple myeloma: A SEER population-based study between two therapeutic eras

This retrospective study of 26,869 multiple myeloma patients reveals that second primary malignancies (SPMs) increased significantly in the modern treatment era. Driven by solid tumors, the median latency to SPM development dropped from 59 to 43.5 months. Consequently, researchers recommend enhanced cancer surveillance for survivors, particularly during the first 7.5 years following diagnosis.